Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover By Makiko Kitamura - 2012-05-24T23:01:00Z GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that’s part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI), its partner on the drug. Glaxo will present data from two of eight late-stage studies, dubbed Harmony 6 and Harmony 7, of the once-weekly drug albiglutide ahead of the American Diabetes Association’s annual meeting next month. Abstracts of those studies will be posted on the ADA website today. Albiglutide, along with the lupus treatment Benlysta and darapladib for heart disease, form a trio of drugs Glaxo has developed with Human Genome. If approved, the product would compete with existing medicines ... Continue reading →
May 25 (Bloomberg) -- Bloomberg's Shannon Pettypiece reports on a catheter made by Medtronic Inc. that is used in an experimental 20-minute procedure to treat hypertension by cauterizing nerves near the kidneys that control blood pressure. (Source: Bloomberg) For three decades Gael Lander fought for her life against the same high blood pressure that contributed to her father’s fatal heart attack and caused a series of debilitating strokes in her mother. Now Lander’s hard-to-treat hypertension is under control, the result of an experimental 20-minute procedure that cauterized nerves near her kidneys that control blood pressure. The nerves were seared using a catheter made by Medtronic Inc. (MDT), the leader among dozens of companies developing similar products that may help re-energize the medical devices industry with ... Continue reading →